Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2778281 | 0.85 | MEN1 (0.39) | MAPTGAATRPA1MEN1KMT2A | |
| Maleic Acid SCHEMBL2778279 | 0.85 | MEN1 (0.39) | MAPTGAATRPA1MEN1KMT2A | |
| SCHEMBL11499806 | 0.80 | GAA (0.43) | MAPTGAATRPA1MEN1KMT2A | |
| SCHEMBL11162416 | 0.80 | MEN1 (0.44) | MAPTGAATRPA1MEN1KMT2A | |
| SCHEMBL14128978 | 0.80 | TRPA1 (0.44) | MAPTGAATRPA1MEN1KMT2A | |
| SCHEMBL7456203 | 0.80 | TRPA1 (0.43) | MAPTGAATRPA1MEN1KMT2A | |
| SCHEMBL20067129 | 0.80 | SMN1; SMN2 (0.43) | MAPTGAATRPA1MEN1KMT2A | |
| SCHEMBL8203995 | 0.80 | BCHE (0.44) | MAPTTRPA1MEN1KMT2AUSP2 | |
| SCHEMBL5138230 | 0.80 | TRPA1 (0.47) | MAPTGAATRPA1MEN1KMT2A | |
| SCHEMBL20067134 | 0.80 | ROS1 (0.42) | MAPTGAATRPA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011091050-A1 | OLIGOMER-TRICYCLIC CONJUGATES | NEKTAR THERAPEUTICS (US) | 2011-07-28 | — | — | WO | claimed |
| JP-2011504928-A | — | — | 2011-02-17 | — | — | JP | claimed |
| EP-2222342-A1 | OLIGOMER-TRICYCLIC CONJUGATES | Nektar Therapeutics (US) | 2010-09-01 | — | — | EP | claimed |
| WO-2009073154-A1 | OLIGOMER-TRICYCLIC CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-06-11 | — | — | WO | claimed |
| US-6103715-A | COMPOUNDS THAT BIND TO THE DOPAMINE D4 RECEPTOR AND THEIR USE AS ANXIOLYTIC AGENTS, TREATMENT FOR SCHIZOPHRENIA, AND DRUG SCREENING; SIDE EFFECT REDUCTIOON | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-08-15 | — | — | US | claimed |
| EP-0736024-A1 | N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS | Allelix Biopharmaceuticals Inc. (CA) | 1996-10-09 | — | — | EP | claimed |
| US-5561127-A | TREATING ANXIETY, SCHIZOPHRENIA | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1996-10-01 | — | — | US | claimed |
| WO-1996019479-A1 | MUSCARINIC RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (US) | 1996-06-27 | — | — | WO | claimed |
| WO-1995017400-A1 | N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-06-29 | — | — | WO | claimed |
| US-12403143-B2 | Pharmaceutical composition for treating functional psychiatric disorders | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "VALENTEK" (RU) | 2025-09-02 | — | — | US | disclosed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250101104-A1 | BISPECIFIC MOLECULE WITH TUNABLE AFFINITY TO A TARGETED ANTIGEN | MABSWITCH INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250064992-A1 | IMAGING METHOD FOR DESIGNER RECEPTOR, ANTAGONIST OR AGONIST, PHARMACEUTICAL, AND COMPANION DIAGNOSTIC AGENT | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2025-02-27 | — | — | US | disclosed |
| CN-119497589-A | Therapeutic combinations, compositions and methods for designing and producing conditions that promote mental well-being | 心境设计实验室股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| EP-0035714-A2 | 10-Substituted-5-cyanomethylene-10,11-dihydro-dibenzo-(a,d)-cycloheptenes, process for their preparation and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1981-09-16 | — | — | EP | disclosed |
| EP-0019172-A1 | 6-Substituted 11-alkylene-morphantridines, process for preparing them and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1980-11-26 | — | — | EP | disclosed |
| US-4191760-A | ANTISCHIZOPHRENICS | ABBOTT LABORATORIES (US) | 1980-03-04 | — | — | US | disclosed |
| US-4096261-A | ANTISCHIZOPHRENICS | ABBOTT LABORATORIES (US) | 1978-06-20 | — | — | US | disclosed |
| US-4054572-A | Hexahydro pyridine [1,2d] dibenza [b,f] (1,4)-diazepines | AKZONA INCORPORATED (US) | 1977-10-18 | — | — | US | disclosed |
| US-3908010-A | Basically substituted heterocycles as anti-emetics | WANDER AG DR A | 1975-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064992-A1 | IMAGING METHOD FOR DESIGNER RECEPTOR, ANTAGONIST OR AGONIST, PHARMACEUTICAL, AND COMPANION DIAGNOSTIC AGENT | HTR3D, CHRNA4, CHRNA3 | MAPT 1515/4885GAA 4485/4885TRPA1 646/4885 |
| US-12403143-B2 | Pharmaceutical composition for treating functional psychiatric disorders | HTR5A, HTR2C, HTR2A | MAPT 1179/4885GAA 3369/4885TRPA1 1158/4885 |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | MAPT 2221/4885GAA 4434/4885TRPA1 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.